A safety signal is a reason to investigate, not a verdict about a medicine. Your operational task is to move evidence through distinct decisions, preserve uncertainty and route each decision to the person authorised to make it.
What you will learn
Distinguish an adverse-event report, statistical alert, validated signal, assessed risk and benefit-risk decision: Signal-management responsibilities and surveillance planning → lifecycle classifications.
Map detection, validation, prioritisation, assessment, action and follow-up: Signal-management responsibilities and surveillance planning → lifecycle decisions.
Separate marketing authorisation holder validation from authority confirmation: Signal-management responsibilities and surveillance planning → accountable roles.
Assign scientific, medical, statistical, epidemiological, qualified person for pharmacovigilance, regulatory and committee contributions: Signal-management responsibilities and surveillance planning → decision ownership.
Distinguish legislation, guidance, International Council for Harmonisation recommendations and company procedures: Signal-management responsibilities and surveillance planning → sources of obligations.
Estimated time
20-25 minutes, plus optional practice.
Blueprint mapping
Signal-management responsibilities and surveillance planning → Signal lifecycle and accountable roles → domain weight 10%; this topic has no separately supplied weight.
Learning baseline
5 November 2026, as represented in the supplied course blueprint. Product-specific requirements and controlled procedures determine operational implementation.
Prerequisites
None.
Key outputs
Choose the correct evidence status, next lifecycle decision and authorised owner; produce a traceable handoff.
WHY
Why it matters
Calling an alert a proven risk can distort a committee recommendation; treating a concerning clinical pattern as a mere reporting artefact can delay assessment.
A completed assessment does not implement an action. Decisions need owners, authorised approval, deliverables and follow-up.
The supplied November 2026 blueprint describes changes to EU signal workflows while retaining monitoring and safety-action responsibilities. A workflow change therefore requires a controlled responsibility check.
Scope: This lesson teaches job decisions within the supplied blueprint. The certificate is a training outcome; it does not confer regulatory authority or independent authority to alter product information.
KEY TERMS
Key Terms & Must-Know Facts
Adverse-event report
A report describing an untoward medical occurrence associated in time with medicine use; the report alone does not establish causation.
Statistical alert
A screening output that meets a specified statistical rule and requires interpretation.
Signal
Information suggesting a new potentially causal association, or a new aspect of a known association, that warrants verification.
Detection
Identification of information that may merit signal evaluation from one or more safety sources.
Validation
Documented evaluation of whether the available information sufficiently supports further signal analysis.
Authority confirmation
A distinct authority-side signal-management step where applicable; it is not established by an internal company validation decision.
Prioritisation
Assignment of review urgency and resources according to the potential importance of the issue.
Assessment
Integrated evaluation of evidence, alternative explanations, uncertainties and possible safety implications.
Assessed risk
A risk conclusion reached after evaluating evidence, with its uncertainty and context recorded; not a synonym for every validated signal.
Benefit-risk decision
An authorised judgment integrating the safety evidence with therapeutic benefits and available options.
Marketing authorisation holder
The organisation holding the marketing authorisation, abbreviated MAH; delegated work does not remove retained accountability.
Qualified person for pharmacovigilance
The QPPV, an EU pharmacovigilance oversight role whose involvement follows applicable responsibilities and controlled escalation arrangements.
Table 1. Evidence status and permissible interpretation
Status
What it supports
What it does not establish
Individual report
Case review, follow-up and applicable reporting evaluation
A population risk estimate
Statistical alert
Verification of counts, methods and clinical context
Causation or incidence
Validated signal
Further analysis with assigned ownership
A confirmed adverse reaction
Assessment conclusion
A documented interpretation and recommendation
Automatic permission to implement every recommendation
Authorised decision
Defined action within the decision-maker's remit
Evidence that the action has been completed or effective
Must-know facts
Clinical information can initiate a signal even without a statistical alert.
Signal validation and individual case validity answer different questions.
MAH validation does not substitute for an applicable authority confirmation step.
Urgent safety evaluation can run in parallel with routine assessment.
Delegated execution requires documented controls and retrievable records.
A signal can be closed with a rationale or revisited when material new evidence emerges.
CORE
Core content
1.1.1.1 1. Classify evidence before choosing the next step
A Explanation
WHY THIS IS TESTED: The same data can support investigation without supporting a causal conclusion. Choose the status demonstrated by the record; reject a more definitive label that requires evidence not yet available.
Separate the observation from the interpretation. A report describes an occurrence. A statistical alert describes a screening result. Validation asks whether a potential association deserves further analysis. Assessment evaluates the total evidence. A benefit-risk decision adds therapeutic context and authorised judgment. These are decision categories, not an inevitable progression toward a harmful-product conclusion.
A signal may concern an entirely new association or a new aspect of an established association, such as a potentially affected subgroup. Conversely, an alert may be explained by duplicate reports or publicity. See Fig 1 for the decision boundary.
Fig 1. Observation versus conclusion Exam takeaway: Match the claim to the evaluation actually completed.
flowchart TD; A[Safety information] --> B{What is documented?}; B --> C[Report or screening output]; B --> D[Signal validation decision]; B --> E[Integrated assessment]; C --> F[Verify before stronger claims]; D --> F; E --> G[Conclusion with uncertainty];
Report and alert comparison Exam takeaway: Neither a case narrative nor a screening threshold independently proves causation.
{"prompt":"Educational vector comparison on white background: left a fictional adverse-event case narrative labelled Report, right a database screening worksheet labelled Statistical alert. Beneath both place Investigation input, not causal proof. No numerical risk estimates, no patient identifiers, blue and gray with amber accent, generous margins, no figure numbers.","caption":"Report and alert comparison","size":"1024x1024"}
Evidence classification flow Exam takeaway: Preserve the distinction between information received and conclusions reached.
Identify the source
Check the completed evaluation
Assign the supported status
Record the next decision
B Worked example
A 68-year-old woman with diabetes and osteoarthritis is described in a suspected liver-injury report after starting Medicine A. Her mild anaemia is also recorded. A dashboard shows increased reporting for the same product-event pair, and a colleague calls the risk confirmed because the association appears twice.
Identify task: Determine the supported status and most appropriate next step.
Extract facts: There is a case report and a screening output; neither an integrated review nor a documented validation conclusion is provided.
Apply rule: Treat both as investigation inputs. Verify whether the case contributes to the dashboard output, and review available clinical information.
Eliminate: Two appearances are not necessarily independent evidence. Age, comorbidities and anaemia do not establish or exclude the association.
Verify: Record source linkage, case limitations, the assigned reviewer and the next evaluation.
C Exam trap
Common traps & distractors: Calling a threshold-crossing result a demonstrated risk is tempting because a numeric threshold looks objective. Single eliminating clue: only a screening decision has been completed.
D Checkpoint MCQ
A verified dashboard alert has no documented clinical evaluation. Which status is best supported?
A. Statistical alert requiring evaluation.
B. Validated signal requiring assessment.
C. Assessed risk requiring a recommendation.
D. Benefit-risk decision requiring implementation.
Answer: A. A is right because verification supports the screening output, not a later clinical decision. B is tempting because verification sounds like validation, but clinical signal validation is not documented. C is tempting because the alert concerns safety, but integrated assessment is absent. D is tempting because surveillance informs action, but no authorised benefit-risk judgment has occurred.
If you missed this: Review Classify evidence before choosing the next step - focus on the completed evaluation, not the strength of the label.
1.1.1.2 2. Use lifecycle gates without creating a waiting queue
A Explanation
WHY THIS IS TESTED: Correct sequencing must support timely decisions without allowing routine process gates to delay urgent safety escalation.
Detection identifies a candidate issue. Validation establishes whether further analysis is justified. Prioritisation assigns urgency and ownership. Assessment integrates evidence. Action translates an authorised conclusion into deliverables. Follow-up checks completion and what happens next. Reassessment may return the issue to an earlier stage.
Do not merge MAH validation with authority confirmation. Record the actor, decision and jurisdictional pathway explicitly. Authority confirmation, where applicable, does not mean causation has been established. Internal status labels should make this distinction visible.
The supplied blueprint names GVP Module IX Rev. 1 and implementing guidance for continuing EU safety-information obligations. It describes emerging-safety-issue notification as soon as possible and no later than three working days after the issue is established as an emerging safety issue. This is a distinct pathway from individual case reporting and from the removed standalone validated-signal notification workflow. Detailed applicability belongs in Current EU Signal Obligations and EU and U.S. Escalation Pathways.
Use urgent assessment alongside routine work when needed; do not wait for the next committee calendar slot to initiate the applicable escalation evaluation. See Fig 2.
Fig 2. Routine lifecycle with an urgent route Exam takeaway: A potential urgent issue requires immediate routing evaluation alongside routine signal work.
flowchart TD; A[Detect information] --> B[Validate and record]; B --> C[Prioritise and assign]; C --> D[Assess evidence]; D --> E[Authorise action and follow up]; A --> U{Urgent concern?}; B --> U; U -->|Yes| V[Activate controlled escalation]; V --> D;
Separate organisational decisions Exam takeaway: Company validation and an applicable authority confirmation step require separate records.
flowchart TD; A[Potential association] --> B[MAH validation decision]; B --> C[Document internal status]; C --> D{Authority pathway applicable?}; D -->|Yes| E[Record authority step separately]; D -->|No| F[Continue applicable company process]; E --> F;
Validation and confirmation records Exam takeaway: The decision-maker must be identifiable in every signal-status entry.
{"prompt":"Clean blue and gray vector diagram of two separate fictional record cards: MAH validation and Authority confirmation where applicable. Each card has fields Actor, Date, Decision, Rationale. Use separate outlined boxes with no equals sign, no approval of causation, white background and generous margins, no figure numbers.","caption":"Validation and confirmation records","size":"1024x1024"}
Urgent route beside routine review Exam takeaway: Urgent escalation evaluation does not wait for a scheduled committee meeting.
{"prompt":"Operational educational vector illustration: a safety reviewer sees a concerning fictional case cluster; two arrows lead to Routine assessment and Urgent escalation evaluation. An amber urgency icon marks the second route, while both routes retain documentation icons. White background, cool blue and gray, no deadlines or treatment instructions, no figure numbers.","caption":"Urgent route beside routine review","size":"1024x1024"}
A reviewer receives reports involving adults aged 54 and 72 with atrial fibrillation and chronic kidney disease; one also has obesity. An unrelated mildly raised cholesterol result appears in a narrative. The reports describe a potentially important new safety pattern. The routine committee meets next month, and an internal signal-validation form is still being completed.
Identify task: Decide whether administrative completion should precede urgency evaluation.
Extract facts: The pattern may be important; neither formal emerging-safety-issue status nor a specific reporting obligation has yet been established.
Apply rule: Activate the controlled urgency evaluation and involve the designated medical, QPPV and regulatory contacts as applicable, while continuing documentation.
Eliminate: The future meeting date is not a reason to defer evaluation. The cholesterol result does not resolve the reported pattern. Comorbidities require analysis, not automatic dismissal.
Verify: Record awareness, evaluations, any established trigger, applicable clock, owner and action. Do not invent a notification deadline from incomplete facts.
C Exam trap
Wrong answer: Wait for routine committee review before checking urgent obligations. It is tempting because committees provide oversight. Single eliminating clue: the information may require an urgent pathway whose evaluation cannot depend on that meeting date.
D Checkpoint MCQ
An internal record states 'validated by the MAH'. What can the reviewer conclude?
A. The applicable authority has confirmed the signal.
B. A company validation decision supports further analysis.
C. The association has been established as a risk.
D. A product-information change has been authorised.
Answer: B. A is tempting because both processes concern signal status, but the actor is explicitly the MAH. B is right because validation supports further analysis. C is tempting because validation sounds definitive, but assessment remains necessary. D is tempting because validation can lead to action, but authorisation of that action is a separate decision.
If you missed this: Review Use lifecycle gates without creating a waiting queue - focus on whose decision the status records.
Quick Recall:
Does a signal require a statistical alert? No; clinical information can initiate evaluation.
Does MAH validation establish authority confirmation? No.
What runs alongside routine work when necessary? Controlled urgent escalation evaluation.
1.1.1.3 3. Assign contributions, approval authority and retained accountability
A Explanation
WHY THIS IS TESTED: A technically sound analysis can fail operationally when nobody owns the next decision or a contributor acts beyond delegated authority.
Separate the evidence contributor, review owner, authorised decision-maker and implementation owner. One person may hold more than one role, but the record must still identify the distinct responsibilities. Role titles alone do not define authority; use controlled procedures, delegation records and committee terms of reference.
Table 2. Contributions and authorisation boundaries
Role
Typical contribution
Boundary to preserve
Scientific or signal lead
Integrates sources, maintains the issue record and coordinates assessment
Does not assume every regulatory commitment is within personal authority
Medical reviewer
Evaluates clinical patterns, case relevance and alternative explanations
Clinical interpretation does not independently authorise every regulatory action
Statistician
Verifies calculations, assumptions and interpretation limits
A statistical output does not determine causation alone
Epidemiologist
Evaluates population context, bias, confounding and evidence-generation options
Observational associations need contextual interpretation
QPPV
Provides applicable EU pharmacovigilance oversight and escalation involvement
Do not infer a universal approval requirement for every worksheet
Regulatory professional
Checks applicable pathways, submission implications and product-information interfaces
Uses authorised decisions and applicable requirements rather than informal assumptions
Safety committee
Challenges evidence and records recommendations or decisions within its remit
Its remit determines whether it recommends or approves
MAH and delegated provider
MAH controls arrangements; provider performs specified tasks
Task delegation does not erase retained MAH accountability
When handing off an issue, specify the question, evidence version, decision needed, recipient, due date or trigger, and escalation route. A recipient copied into a message is not necessarily an assigned owner. See Fig 3.
flowchart TD; A[Scientific and clinical evidence] --> C[Assessment owner integrates]; B[Statistical and epidemiological appraisal] --> C; C --> D[Recommendation]; D --> E[Authorised decision under defined remit]; E --> F[Named implementation owner];
Multidisciplinary review with defined ownership Exam takeaway: Several reviewers can contribute while one named owner coordinates the assessment.
{"prompt":"Professional vector illustration of a pharmacovigilance evidence-review table with cards labelled Scientific, Medical, Statistics, Epidemiology, QPPV, Regulatory. The cards feed a central assessment folder labelled Named owner. A separate committee decision record is nearby. No real people or logos, white background, blue and gray with amber accent, no figure numbers.","caption":"Multidisciplinary review with defined ownership","size":"1024x1024"}
Ownership assignment flow Exam takeaway: A handoff is complete only when the required decision and responsible recipient are explicit.
Define the decision needed
Assign evidence contributors
Name the review owner
Confirm approval authority
Track implementation responsibility
B Worked example
A provider scientist reviews reports about a 61-year-old man with hypertension and chronic kidney disease and a 47-year-old woman with diabetes and obesity. A normal sodium result is prominently displayed. The scientist recommends a product-information change. The contract permits signal assessment, and the scientist has completed this certificate. The team proposes that the scientist implement the change immediately.
Identify task: Determine whether analytical responsibility includes implementation authority.
Extract facts: Assessment is delegated; authority to implement the proposed regulatory change is not supplied.
Apply rule: Submit the documented recommendation through the MAH's defined medical, regulatory, QPPV and committee arrangements as applicable.
Eliminate: Training demonstrates learning, not regulatory authority. A normal laboratory result does not settle the broader association or the delegation question.
Verify: Confirm the decision-maker's remit, record approval or rejection and assign implementation and follow-up owners.
C Exam trap
Wrong answer: Treat the provider's assessment contract as permission to implement a regulatory change. This is tempting because the provider performed the technical work. Single eliminating clue: the stated delegation covers assessment only.
D Checkpoint MCQ
A committee endorses a recommendation, but its terms of reference authorise recommendations only. What is the most appropriate next step?
A. Treat endorsement as final implementation approval.
B. Route the recommendation to the designated authorised decision-maker.
C. Ask the statistician to authorise implementation after calculation verification.
D. Transfer implementation approval to the contracted assessment provider.
Answer: B. A is tempting because committee consensus appears authoritative, but the remit is limited. B is right because approval must follow the defined authority. C is tempting because methodological verification strengthens the evidence, but it does not confer approval authority. D is tempting because the provider knows the assessment, but its delegation does not automatically include implementation approval.
If you missed this: Review Assign contributions, approval authority and retained accountability - focus on the documented remit.
1.1.1.4 4. Make controlled decisions and close the follow-up loop
A Explanation
WHY THIS IS TESTED: Learners must distinguish a source of obligations from a local execution rule, and a decision record from evidence that action was completed.
Binding legislation establishes applicable legal obligations. Regulatory guidance describes regulatory expectations and implementation approaches; do not label every guidance statement as a statutory provision. International Council for Harmonisation recommendations provide harmonised technical concepts, with applicability dependent on regional implementation. Company procedures convert applicable requirements into controlled tasks, responsibilities and records. A company procedure cannot remove an applicable legal obligation.
The supplied blueprint attributes EU competence and training expectations to Regulation (EU) No 520/2012, Article 10, and quality, traceability and accountability requirements to the related provisions listed in the blueprint. It also identifies 2025 amendments affecting EU operational workflows. Those references support maintaining controlled processes; they do not establish that this certificate, a particular course duration or a specified renewal interval is legally mandatory.
For an assessment outcome, document the question, evidence cut, conclusion, uncertainty, decision-maker, action, owner and follow-up trigger. A conclusion may support no immediate change, further evidence generation or action. Closure requires a reason and an appropriate monitoring or reopening arrangement, rather than an unsupported claim that no risk exists. See Fig 4 and Fig 5.
Fig 4. Identify the source of the instruction Exam takeaway: A controlled procedure implements applicable requirements without changing their legal status.
flowchart TD; A[Operational instruction] --> B{Source identified?}; B --> C[Binding legislation]; B --> D[Regulatory guidance]; B --> E[ICH recommendation]; B --> F[Company procedure]; C --> G[Check applicability and controlled implementation]; D --> G; E --> G; F --> G;
Fig 5. Decision to verified follow-up Exam takeaway: Authorisation, implementation and effectiveness are separate checkpoints.
flowchart TD; A[Assessment conclusion] --> B[Authorised decision]; B --> C[Action owner and deliverable]; C --> D[Verify completion]; D --> E[Review outcome or new evidence]; E --> F{Reassessment needed?}; F -->|Yes| A; F -->|No| G[Continue documented monitoring];
Requirement sources and local execution Exam takeaway: Training and procedures support competent work without creating regulatory authority.
{"prompt":"Educational vector comparison of four clearly separated document cards labelled Legislation, Regulatory guidance, ICH recommendations, Company procedure. A small training certificate sits beside a staff competency record, not beside an official authority seal. White background, cool blue and gray, thin outlines, no legal text or logos, no figure numbers.","caption":"Requirement sources and local execution","size":"1024x1024"}
Decision record and follow-up evidence Exam takeaway: An approved action still needs an owner, completion evidence and an outcome review.
{"prompt":"Clean operational vector illustration of a fictional pharmacovigilance decision record with labelled fields Evidence version, Decision, Uncertainty, Authorised owner, Action due, Completion evidence, Reopening trigger. Place three distinct checkboxes beside Authorised, Implemented, Outcome reviewed. No patient identifiers or real product names, white background, blue and gray with amber accent, no figure numbers.","caption":"Decision record and follow-up evidence","size":"1024x1024"}
Controlled close-out flow Exam takeaway: Closure preserves the evidence basis and a route for material new information.
Identify applicable requirements
Record conclusion and uncertainty
Obtain authorised decision
Verify action completion
Define monitoring and reopening
B Worked example
A signal assessment includes a 73-year-old man with heart failure and diabetes. His stable haemoglobin is a distracting finding. After reviewing the cumulative evidence, the team recommends continued monitoring without immediate product-information change. A colleague proposes deleting the record because the signal was not established as a risk; another says course completion is enough to approve closure.
Identify task: Close or continue the issue with a defensible record.
Extract facts: There is an assessment recommendation, but closure approval and follow-up arrangements are not yet documented.
Apply rule: Route the recommendation to the authorised decision-maker, retain the evidence and rationale, and specify monitoring and reopening triggers.
Eliminate: No immediate change does not mean evidence should be deleted. A certificate does not define closure authority. Stable haemoglobin does not resolve the governance question.
Verify: Confirm the disposition, owner, retained evidence version and review trigger are retrievable.
C Exam trap
Wrong answer: Close an issue as soon as the recommendation is written. This is tempting because the scientific work feels finished. Single eliminating clue: the required authorised disposition and follow-up arrangements are missing.
D Checkpoint MCQ
A procedure cites an old notification workflow. Which response is most appropriate?
A. Continue the old workflow until the next scheduled training cycle.
B. Stop monitoring because the cited notification workflow has ended.
C. Route the discrepancy through change control and apply the current authorised process for continuing obligations.
D. Replace the procedure informally with the course summary.
Answer: C. A is tempting because controlled procedures should be followed, but an identified conflict needs timely resolution. B is tempting because a workflow ended, but continuing monitoring and safety-action obligations remain in the supplied blueprint. C is right because it connects current applicability with controlled implementation. D is tempting because the lesson is accessible, but training material is not a substitute for an authorised procedure.
If you missed this: Review Make controlled decisions and close the follow-up loop - focus on controlled resolution of an outdated instruction.
Quick Recall:
Does outsourcing remove retained MAH accountability? No.
What defines committee approval power? Its documented remit and applicable delegation.
What distinguishes closure from deletion? A retained disposition, rationale and follow-up arrangement.
TRAPS
Exam Traps & Differentiators
Most common wrong answer: Select the strongest-sounding conclusion rather than the next justified decision. This is tempting when a vignette contains several concerning details; their presence does not establish that the required evaluation has occurred.
Table 3. Similar labels with different decision consequences
Looks similar
Discriminating question
Operational consequence
Case validity versus signal validation
Are you evaluating an individual case record or a potential association?
Use the relevant process; completing one does not complete the other
Validation versus confirmation
Which organisation made the recorded decision?
Maintain separate MAH and applicable authority statuses
Priority versus causal confidence
Is this a scheduling concern or an evidence conclusion?
High urgency can coexist with considerable uncertainty
Assessment versus benefit-risk decision
Has therapeutic benefit and the decision-maker's remit been integrated?
Route a safety conclusion into the authorised decision process
Recommendation versus implementation
Is there approval and evidence of action completion?
Assign and verify deliverables
Closure versus absence of risk
What evidence and uncertainty support the disposition?
Retain rationale and define reopening arrangements
If the scenario says 'threshold exceeded', think screening verification and interpretation.
If it says 'validated internally', think company decision, not an authority decision.
If it says 'urgent concern before committee', think immediate escalation evaluation.
If it says 'provider contracted for assessment', think scope of delegation.
If it says 'action approved', think implementation evidence still needed.
What comes next: Current EU Signal Obligations develops the November 2026 blueprint's distinction between changed notification workflows and continuing safety responsibilities. No future proposal or adoption date is supplied here; do not treat an anticipated change as effective. Recheck the controlled requirements when processes or product conditions change.
ALGO
Algorithm / Approach
Use this five-step handoff before changing an issue's status. The workflow supports assessment and routing; it does not determine a product-specific regulatory outcome.
1. Classify: State the source and the evaluation actually completed.
2. Triage: Check whether urgent evaluation must run in parallel.
3. Assign: Name the assessment owner, contributors and authorised decision-maker.
4. Decide: Record evidence, uncertainty, applicable pathway and authorised disposition.
5. Verify: Track action completion, monitoring and reopening triggers.
QUIZ
Self-check quiz
Choose the single most appropriate answer. Questions 1-2 provide a short quick check; complete all five to practise integrated decisions.
1. Classification
A product-event pair crosses a screening threshold. Counts have been checked, but no clinical signal review has occurred. What should the issue record say?
A. Statistical alert pending clinical evaluation.
B. Validated signal pending authority confirmation.
C. Assessed risk pending communication.
D. Benefit-risk conclusion pending implementation.
2. Decision ownership
A company validation record is complete. Which statement is justified?
A. The authority has confirmed the issue because validation is complete.
B. The company has documented support for further signal analysis.
C. The product-event relationship is established as causal.
D. The assessment outcome has been approved for implementation.
3. Urgent routing
Potentially important new safety information arrives before a scheduled committee meeting. Applicability of an urgent obligation is not yet established. What is the best next step?
A. Wait for committee validation before initiating urgency evaluation.
B. Use the individual case reporting clock as the signal decision deadline.
C. Activate the controlled urgency evaluation while continuing routine assessment.
D. Treat every new signal as an established emerging safety issue and apply that pathway automatically.
4. Delegated work
A contracted analyst completes a strong assessment and recommends a regulatory action. The delegation covers assessment only. Who should authorise the proposed action?
A. The analyst, because the evidence is technically adequate.
B. The provider manager, because the assessment was outsourced.
C. The designated decision-maker under the MAH's controlled arrangements.
D. The statistician, because independent calculations have been verified.
5. Follow-up
An authorised decision supports no immediate change after assessment. Which record best supports appropriate closure?
A. A closed status and the date of the last committee meeting.
B. A retained rationale, evidence version, uncertainty, owner and monitoring or reopening arrangement.
C. A provider invoice and completed assessment training record.
D. A statement that the absence of action demonstrates the absence of risk.
ANSWERS
Answer key & explanations
1. Answer: A
A: Correct; the checked screening output supports an alert, with clinical evaluation still pending. B: Tempting because verification resembles validation, but no clinical signal decision is described. C: Tempting because the screened event is safety-related, but an assessed risk requires evidence evaluation. D: Tempting because screening ultimately supports decisions, but therapeutic context and authorisation are absent.
If you missed this: Review Classify evidence before choosing the next step - focus on screening verification versus clinical evaluation.
2. Answer: B
A: Tempting because validation and confirmation both describe process gates, but the record identifies a company decision only. B: Correct; validation supports further analysis without predetermining its result. C: Tempting because 'validated' sounds conclusive, but causal assessment is a different question. D: Tempting because a completed form appears to close a task, but assessment and action approval are not documented.
If you missed this: Review Use lifecycle gates without creating a waiting queue - focus on actor-specific status.
3. Answer: C
A: Tempting because committees provide oversight, but an urgent issue needs timely evaluation before the meeting. B: Tempting because individual case clocks are familiar, but they do not replace a distinct escalation-pathway evaluation. C: Correct; urgency can be evaluated while the routine evidence work continues. D: Tempting because it appears precautionary, but a potential concern does not automatically meet the stated emerging-safety-issue trigger.
If you missed this: Review Use lifecycle gates without creating a waiting queue - focus on evaluating the applicable trigger without waiting or assuming it is met.
4. Answer: C
A: Tempting because the analyst understands the evidence, but analytical competence does not extend the delegation. B: Tempting because provider management controls its staff, but outsourcing does not transfer every MAH decision. C: Correct; the controlled arrangements identify the authorised actor while preserving retained accountability. D: Tempting because verified calculations increase confidence, but technical verification does not confer regulatory approval authority.
If you missed this: Review Assign contributions, approval authority and retained accountability - focus on delegated task scope.
5. Answer: B
A: Tempting because status and date establish chronology, but they omit why closure was justified and what follows. B: Correct; these elements preserve the decision basis and a route for material new information. C: Tempting because contract and competence evidence belong in the quality system, but neither records the issue disposition. D: Tempting because no action can look reassuring, but absence of immediate change is not proof of absent risk.
If you missed this: Review Make controlled decisions and close the follow-up loop - focus on retained rationale and reopening arrangements.
RAPID
Rapid review / cheat-sheet
Evidence wording → use the narrowest conclusion supported by the completed evaluation.
Duplicate visibility → check whether apparently separate sources describe the same case.
Urgency and certainty → treat them as separate dimensions of the decision.
Actor-specific status → record who decided, not just what the status is called.
Handoff completeness → specify the decision requested, recipient and trigger or due date.
Committee endorsement → compare the requested action with the committee's remit.
Process change → resolve the applicability question through controlled implementation.
Follow-up quality → distinguish completion evidence from evidence of the action's outcome.
Key points
Classify information before selecting a lifecycle action.
Pair every substantive decision with an authorised owner.
Keep urgent evaluation available alongside routine assessment.
Retain the reasoning and verify what happened after the decision.
End of your free lesson
Keep going with the full Pharmacovigilance Signal Detection and Risk Management Professional Certificate
You just studied the way members do, in the same lesson interface. Full access unlocks every lesson, the question bank and flashcards for a full year.